Evidence map›Paper›PMID 37152188›Full record

ArticleOpen forum infectious diseases2023

Large Diffusion of Severe Acute Respiratory Syndrome Coronavirus 2 After the Successive Epidemiological Waves, Including Omicron, in Guinea and Cameroon: Implications for Vaccine Strategies.

Mamadou Saliou Kalifa Diallo, Marie Amougou-Atsama, Ahidjo Ayouba, Cece Kpamou, Eric Donald Mimbe Taze, Guillaume Thaurignac, Haby Diallo, Nadine Boutgam Lamare, Julie Bouillin, Abdoul Karim Soumah and 9 more

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 3 countries.

Mamadou Saliou Kalifa DialloCentre de Recherche et de Formation en Infectiologie de Guinée, Université Gamal Abdel Nasser de Conakry, Conakry, Guinea.
Marie Amougou-AtsamaCentre de Recherche sur les Maladies Émergentes et Re-Emergentes, Yaounde, Cameroon.
Ahidjo AyoubaTransVIHMI, University of Montpellier, Inserm, Institut de Recherche pour le Developpement, Montpellier, France.ORCID https://orcid.org/0000-0002-5081-1632
Cece KpamouCentre de Recherche et de Formation en Infectiologie de Guinée, Université Gamal Abdel Nasser de Conakry, Conakry, Guinea.
Eric Donald Mimbe TazeFrench National Agency for Research on AIDS and Infectious Diseases, Cameroon Site, Central Hospital of Yaounde, Yaounde, Cameroon.
Guillaume ThaurignacTransVIHMI, University of Montpellier, Inserm, Institut de Recherche pour le Developpement, Montpellier, France.
Haby DialloCentre de Recherche et de Formation en Infectiologie de Guinée, Université Gamal Abdel Nasser de Conakry, Conakry, Guinea.
Nadine Boutgam LamareFaculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon.
Julie BouillinTransVIHMI, University of Montpellier, Inserm, Institut de Recherche pour le Developpement, Montpellier, France.
Abdoul Karim SoumahCentre de Recherche et de Formation en Infectiologie de Guinée, Université Gamal Abdel Nasser de Conakry, Conakry, Guinea.
Sébastien Awono NoahFrench National Agency for Research on AIDS and Infectious Diseases, Cameroon Site, Central Hospital of Yaounde, Yaounde, Cameroon.
Emilande GuichetTransVIHMI, University of Montpellier, Inserm, Institut de Recherche pour le Developpement, Montpellier, France.
Alpha Kabinet KeitaCentre de Recherche et de Formation en Infectiologie de Guinée, Université Gamal Abdel Nasser de Conakry, Conakry, Guinea.
Marie VarloteauxFrench National Agency for Research on AIDS and Infectious Diseases, Cameroon Site, Central Hospital of Yaounde, Yaounde, Cameroon.
Martine PeetersTransVIHMI, University of Montpellier, Inserm, Institut de Recherche pour le Developpement, Montpellier, France.ORCID https://orcid.org/0000-0001-6738-8730
Anne-Cécile Zoung-Kanyi BissekCentre de Recherche sur les Maladies Émergentes et Re-Emergentes, Yaounde, Cameroon.
Abdoulaye ToureCentre de Recherche et de Formation en Infectiologie de Guinée, Université Gamal Abdel Nasser de Conakry, Conakry, Guinea.
Eric DelaporteTransVIHMI, University of Montpellier, Inserm, Institut de Recherche pour le Developpement, Montpellier, France.
Charles KouanfackFrench National Agency for Research on AIDS and Infectious Diseases, Cameroon Site, Central Hospital of Yaounde, Yaounde, Cameroon.
Inserm · FRCentral Hospital of Yaoundé · CMGamal Abdel Nasser University of Conakry · GNUniversité de Dschang · CM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We aimed to estimate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence among the general population in Conakry, Guinea and Yaounde, Cameroon after the coronavirus disease 2019 Omicron wave. Methods: We conducted population-based, age-stratified seroprevalence surveys in Conakry and Yaounde (May and June 2022). We collected demographic and epidemiologic information and dried blood spot samples that were tested for SARS-CoV-2 immunoglobulin G (IgG) antibodies using recombinant nucleocapsid and spike proteins with Luminex technology. Results: Samples were obtained from 1386 and 1425 participants in Guinea and Cameroon, respectively. The overall age-standardized SARS-CoV-2 IgG seroprevalence against spike and nucleocapsid proteins was 71.57% (95% confidence interval [CI], 67.48%-75.33%) in Guinea and 74.71% (95% CI, 71.99%-77.25%) in Cameroon. Seroprevalence increased significantly with age categories. Female participants were more likely than male participants to be seropositive. The seroprevalence in unvaccinated participants was 69.6% (95% CI, 65.5%-73.41%) in Guinea and 74.8% (95% CI, 72.04%-77.38%) in Cameroon. In multivariate analysis, only age, sex, and education were independently associated with seropositivity. Conclusions: These findings show a high community transmission after the different epidemiological waves including Omicron, especially among people aged >40 years. In addition, our results suggest that the spread of SARS-CoV-2 has been underestimated as a significant proportion of the population has already contracted the virus and that vaccine strategies should focus on vulnerable populations.

Indexed as

CameroonGuineapopulation-based surveySARS-CoV-2seroprevalence

Identifiers

PMID37152188
PMCPMC10157752
OpenAlexW4366588922

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.